Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Panagiota-Efstathia Nikolaou"'
Autor:
Andriana Christodoulou, Panagiota-Efstathia Nikolaou, Lydia Symeonidi, Konstantinos Katogiannis, Louisa Pechlivani, Theodora Nikou, Aimilia Varela, Christina Chania, Stelios Zerikiotis, Panagiotis Efentakis, Dimitris Vlachodimitropoulos, Nikolaos Katsoulas, Anna Agapaki, Costantinos Dimitriou, Maria Tsoumani, Nikolaos Kostomitsopoulos, Constantinos H. Davos, Alexios Leandros Skaltsounis, Alexandros Tselepis, Maria Halabalaki, Ioulia Tseti, Efstathios K. Iliodromitis, Ignatios Ikonomidis, Ioanna Andreadou
Publikováno v:
Redox Biology, Vol 76, Iss , Pp 103311- (2024)
Clinical studies have previously established the role of olive products in cardiovascular disease (CVD) prevention, whilst the identification of the responsible constituents for the beneficial effects is still pending. We sought to assess and compare
Externí odkaz:
https://doaj.org/article/4f4fdd05cf5c41da9bd3e91974f80717
Autor:
Panagiota-Efstathia Nikolaou, PhD, MSc, Lara Konijnenberg, MD, Carolien Kuster, Vince van Reijmersdal, MSc, Andor Veltien, BSc, Ioanna Andreadou, PhD, MSc, Niels van Royen, MD, PhD, Robin Nijveldt, MD, PhD, FSCMR
Publikováno v:
Journal of Cardiovascular Magnetic Resonance, Vol 26, Iss , Pp 100378- (2024)
Externí odkaz:
https://doaj.org/article/07936f7a0202408dadf38e490654e574
Autor:
Panagiotis Efentakis, Sofia Lamprou, Manousos Makridakis, Ioanna Barla, Panagiota-Efstathia Nikolaou, Andriana Christodoulou, Costantinos Dimitriou, Nikolaos Kostomitsopoulos, Ioannis Ntanasis-Stathopoulos, Irene Theochari, Maria Gavriatopoulou, Harikleia Gakiopoulou, Androniki Tasouli, Antonia Vlahou, Evangelos Gikas, Nikolaos Thomaidis, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou
Publikováno v:
HemaSphere, Vol 6, Iss 11, p e791 (2022)
Carfilzomib is an irreversible proteasome inhibitor indicated for relapsed/refractory multiple myeloma. Carfilzomib toxicity includes renal adverse effects (RAEs) of obscure pathobiology. Therefore, we investigated the mechanisms of nephrotoxicity de
Externí odkaz:
https://doaj.org/article/fc5d420a1abb40f487384cc2e97d1092
Autor:
Panagiotis Efentakis, Garyfalia Psarakou, Aimilia Varela, Eleni Dimitra Papanagnou, Michail Chatzistefanou, Panagiota-Efstathia Nikolaou, Costantinos H. Davos, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios Athanasios Dimopoulos, Ioanna Andreadou, Evangelos Terpos
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 20, p 10956 (2021)
Background: Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. We have previously established a translational model of carfilzomib c
Externí odkaz:
https://doaj.org/article/cb9369184c554136abe71c61dc073850
Autor:
Panagiotis Efentakis, Hendrik Doerschmann, Claudius Witzler, Svenja Siemer, Panagiota-Efstathia Nikolaou, Efstathios Kastritis, Roland Stauber, Meletios Athanasios Dimopoulos, Philip Wenzel, Ioanna Andreadou, Evangelos Terpos
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 15, p 5185 (2020)
Background: Carfilzomib’s (Cfz) adverse events in myeloma patients include cardiovascular toxicity. Since carfilzomib’s vascular effects are elusive, we investigated the vascular outcomes of carfilzomib and metformin (Met) coadministration. Metho
Externí odkaz:
https://doaj.org/article/f86136bf69604c8488d656a5c7bea6ef
Autor:
Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H. Davos, Aimilia Varela, Constantinos A. Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari, Ignatios Ikonomidis, Nikolaos Kostomitsopoulos, Maria F. Brizzi, George Dimitriadis, Efstathios K. Iliodromitis
Publikováno v:
Frontiers in Physiology, Vol 8 (2017)
Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced cardiovascular death but is unknown if it reduces myocardial infarction. We sought to investigate: (i) the effect of EMPA on myocardial function and infarct size after isch
Externí odkaz:
https://doaj.org/article/d1a93a992feb4ed0be01f153767955bf
Autor:
Panagiota Efstathia Nikolaou, Nikolaos Mylonas, Manousos Makridakis, Marina Makrecka-Kuka, Aikaterini Iliou, Stelios Zerikiotis, Panagiotis Efentakis, Stavros Kampoukos, Nikolaos Kostomitsopoulos, Reinis Vilskersts, Ignatios Ikonomidis, Vaia Lambadiari, Coert J. Zuurbier, Agnieszka Latosinska, Antonia Vlahou, George Dimitriadis, Efstathios K. Iliodromitis, Ioanna Andreadou
Publikováno v:
Basic research in cardiology, 117(1):27. D. Steinkopff-Verlag
Major clinical trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) exhibit protective effects against heart failure events, whereas inconsistencies regarding the cardiovascular death outcomes are observed. Therefore, we aimed to compare
Autor:
M Tsoumani, Antonia Vlahou, Manousos Makridakis, Androniki Tasouli, Maria Felice Brizzi, Constantinos A. Dimitriou, Nikolaos Kostomitsopoulos, Coert J. Zuurbier, George Dimitriadis, Fairouz Abu Qourah, Constantinos H. Davos, Apostolos Klinakis, Panagiotis Efentakis, Zoi Kanaki, Efstathios K. Iliodromitis, Aimilia Varela, Ioanna Andreadou, Panagiota Efstathia Nikolaou, Saveria Femminò
Publikováno v:
Antioxidants & redox signaling, 34(7), 551-571. Mary Ann Liebert Inc.
Aims: Empagliflozin (EMPA) demonstrates cardioprotective effects on diabetic myocardium but its infarct-sparing effects in normoglycemia remain unspecified. We investigated the acute and chronic effect of EMPA on infarct size after ischemia-reperfusi
Autor:
Gerd Heusch, Péter Ferdinandy, Adriana Adameova, Panagiota-Efstathia Nikolaou, Inês Falcão-Pires, Ioanna Andreadou, Sandrine Lecour, Gemma Vilahur, Petra Kleinbongard, Nicholas J. Woudberg, Rainer Schulz, Lina Badimon
Publikováno v:
Br J Pharmacol
Hyperlipidaemia is a well-established risk factor for cardiovascular diseases and therefore, many animal model have been developed to mimic the human abnormal elevation of blood lipid levels. In parallel, extensive research for the alleviation of isc
Autor:
Maria Tsoumani, Panagiota Efstathia Nikolaou, Aikaterini Argyropoulou, Ioulia Tseti, Sofia Mitakou, Ioanna Andreadou
Publikováno v:
Molecules; Volume 27; Issue 4; Pages: 1221
Hot flashes are considered the most bothersome complaint during menopause. Although hormone therapy is an effective option to relieve hot flashes, it has been associated with significant side effects. The aim of our study is to suggest a novel combin